Long-term investor Boston Scientific is paying $295m upfront for the 73% of the ablation technology developer it does not own.

Farapulse, a US-based ablation technology developer spun out of University of Iowa, has agreed to an acquisition by medical device and existing shareholder Boston Scientific for $295m.

Boston Scientific currently owns a 27% stake in the company and is taking up an option to purchase all the remaining shares. It may pay out an additional $92m in milestone payments, as well as an undisclosed amount in revenue-based payments over the next three years.

Founded in 2014 as Iowa Approach, Farapulse…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn